Reduced fidelity refers to an increase in errors during a copying or replication process. The term appears most often in two contexts: molecular biology, where it describes DNA or RNA polymerases that make more mistakes than normal when copying genetic material, and clinical research, where it describes a failure to deliver a treatment exactly as designed during a study. In both cases, “fidelity” means accuracy, and “reduced fidelity” means that accuracy has dropped, with consequences that range from cancer risk to misleading drug trial results.
Reduced Fidelity in DNA Replication
Every time a cell divides, specialized enzymes called DNA polymerases copy the entire genome. High-fidelity polymerases are remarkably precise, making as few as 25 errors per 1 million bases copied. But not all polymerases perform at that level. Some are inherently less accurate, producing error rates 10 to more than 100 times higher. These “reduced fidelity” or “low-fidelity” polymerases insert the wrong building block, skip a letter, or add an extra one, and they do so at rates that can reach roughly 3,000 errors per million bases.
The key reason some polymerases are more accurate than others comes down to a built-in spellcheck system called proofreading. High-fidelity polymerases have a specialized editing domain that detects a freshly placed wrong letter, backs up, clips it out, and tries again. This proofreading step alone improves accuracy by about 200-fold. Polymerases with reduced fidelity typically lack this editing ability or have mutations that weaken it. Without effective proofreading, errors made during the initial copying step simply stay in the new DNA strand.
A good example is human DNA polymerase theta, a family A polymerase that has no detectable proofreading activity. It generates single base substitution errors at an average rate of about 2.4 per 1,000 bases and inserts extra letters into repetitive DNA sequences at rates exceeding 1 in 100 in some contexts. That makes it roughly comparable in accuracy to family Y polymerases, a group already known for being error-prone. Structural analysis shows that polymerase theta contains extra amino acid segments not found in its more accurate relatives, and these insertions likely help stabilize misaligned DNA strands, making errors even more frequent.
Why Cells Use Low-Fidelity Polymerases
If reduced fidelity causes more mutations, why do cells keep these sloppy enzymes around? The answer is that sometimes copying damaged DNA imperfectly is better than not copying it at all. When DNA is damaged by UV light, chemicals, or other insults, the high-fidelity polymerases responsible for normal replication can stall completely. They are too precise to work with a distorted template. Low-fidelity polymerases step in and push past the damage, a process called translesion synthesis. The cost is more errors, but the benefit is that replication continues and the cell survives.
Bacteria use a version of this strategy called the SOS response. When a bacterial cell detects severe DNA damage, it activates a set of emergency repair genes. Among them is DNA polymerase V, a low-fidelity enzyme that can copy past lesions that would otherwise block replication. This is sometimes described as a double-edged sword: the cell gets error-free repair of some damage alongside error-prone copying of the rest. The tradeoff generates mutations, some of which may be harmful, but others can help the population adapt to the stress that caused the damage in the first place.
The immune system also exploits reduced fidelity deliberately. During the process of generating antibody diversity, certain low-fidelity polymerases introduce mutations into immunoglobulin genes at elevated rates. This “somatic hypermutation” produces a wide variety of slightly different antibodies, allowing the immune system to fine-tune its response to new threats.
How Reduced Fidelity Drives Cancer
When the mechanisms that keep replication accurate break down permanently, the result is a “mutator phenotype,” a cell that accumulates mutations far faster than normal. This is one of the central drivers of cancer development. Cells need multiple mutations in growth-controlling genes before they become cancerous, and a higher mutation rate dramatically increases the odds of hitting those genes.
The strongest early evidence for this connection came from Lynch syndrome, a hereditary condition in which the mismatch repair system (a second layer of error correction that catches mistakes the polymerase’s proofreading missed) is defective. People with Lynch syndrome have a sharply elevated risk of colorectal cancer, and the signature of their tumors is microsatellite instability, a pattern of errors in repetitive DNA sequences that accumulate when mismatch repair fails. Defective mismatch repair also turns up in sporadic (non-inherited) cancers of the uterus, lung, and stomach.
More recently, researchers have identified cancer-driving mutations in the proofreading domains of the two main replicative polymerases themselves, Pol delta and Pol epsilon. A survey of over 10,900 tumor samples in The Cancer Genome Atlas found 92 proofreading domain mutations in Pol epsilon alone among hypermutant tumors. These mutations disable the metal-binding residues that power the editing reaction, effectively turning a high-fidelity polymerase into a low-fidelity one. In mouse studies, animals engineered with defective Pol delta proofreading developed skin and lung cancers at high rates, with over 95% dying of cancer by 15 months. Mice with defective Pol epsilon proofreading developed intestinal cancers and blood cancers, surviving somewhat longer but still at dramatically elevated risk. In humans, specific Pol epsilon mutations have been linked to increased breast cancer risk and worse outcomes in lung cancer.
Reduced Fidelity in Viruses
RNA viruses naturally operate with reduced fidelity compared to DNA-based organisms. Their copying enzymes lack the proofreading domains that DNA polymerases use, so their baseline error rates are much higher. This is not a flaw but a strategy. The high error rate generates enormous genetic diversity within a viral population, allowing the virus to adapt rapidly to immune pressure, new host species, or antiviral drugs.
That diversity is a balancing act. Too little fidelity and the virus accumulates so many harmful mutations that it can no longer function, a concept researchers call “error catastrophe.” Too much fidelity and the virus loses its ability to evolve quickly. Coronaviruses are an interesting exception among RNA viruses because they do have a limited proofreading mechanism, which may be one reason they can maintain much larger genomes than most other RNA viruses. Altering coronavirus fidelity in either direction, making it sloppier or more precise, can shift the balance between virulence and attenuation, immune escape and vulnerability.
Reduced Fidelity in Clinical Research
Outside of biology, “reduced fidelity” has an entirely different but equally important meaning in healthcare research. In clinical trials, intervention fidelity refers to how closely researchers and clinicians actually deliver a treatment according to its designed protocol. When fidelity drops, meaning the treatment is delivered inconsistently, incompletely, or with unplanned modifications, the trial’s results become unreliable.
A meta-epidemiological study examining this relationship found a clear linear connection between fidelity and treatment effect sizes across randomized controlled trials. Studies with poor or absent fidelity monitoring tended to report larger but less precise treatment effects. In other words, sloppy delivery made treatments look more effective than they actually were. When researchers statistically adjusted for fidelity, the pooled treatment effects in four separate meta-analyses shrank from moderate to small, or from small to negligible. This matters for patients because it means some treatments adopted based on inflated trial results may be less effective in practice than expected, while other treatments that appeared weak in low-fidelity trials might actually work better than the data suggested.
The practical takeaway is that how carefully a treatment is delivered during a study is just as important as what the treatment is. Reduced intervention fidelity introduces noise that can distort conclusions in either direction, making the entire evidence base less trustworthy when fidelity goes unmonitored.